Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01781572
Title A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis



Binimetinib + Ribociclib

Age Groups: adult
Covered Countries USA | ITA | DEU

Facility Status City State Zip Country Details
University of California, Dept of Oncology San Francisco California 94101 United States Details
California Pacific Medical Center Onc Dept San Francisco California 94120-7999 United States Details
Karmanos Cancer Institute Dept of Oncology Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center Dept Oncology New York New York 10021 United States Details
Columbia University Medical Center- New York Presbyterian Onc Dept. New York New York 10032 United States Details
Vanderbilt University Medical Center SC - Dept of Oncology . Nashville Tennessee 37232 United States Details
University of Texas/MD Anderson Cancer Center Dept of Onc. Houston Texas 77030-4009 United States Details
Pfizer Investigative Site 1003 North Sydney New South Wales 2060 Australia Details
Pfizer Investigative Site 1002 Westmead New South Wales 2145 Australia Details
Pfizer Investigator Site 1001 East Melbourne Victoria Australia Details
Pfizer Investigative Site 1050 Essen 45147 Germany Details
Pfizer Investigative Site 1053 Gera 07548 Germany Details
Pfizer Investigative Site 1052 Hannover 30625 Germany Details
Pfizer Investigative Site 1051 Muenchen 80336 Germany Details
Pfizer Investigative Site 1101 Napoli 80131 Italy Details
Pfizer Investigative Site 1151 Utrecht The Netherlands 3508 GA Netherlands Details
Pfizer Investigative Site 1150 Nijmegen 6525 GA Netherlands Details
*Shaded cells indicate that there was no data available from for the field